These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33080150)

  • 1. Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
    Tosoian JJ; Trock BJ; Morgan TM; Salami SS; Tomlins SA; Spratt DE; Siddiqui J; Kunju LP; Botbyl R; Chopra Z; Pandian B; Eyrich NW; Longton G; Zheng Y; Palapattu GS; Wei JT; Niknafs YS; Chinnaiyan AM
    J Urol; 2021 Mar; 205(3):732-739. PubMed ID: 33080150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MyProstateScore in men considering repeat biopsy: validation of a simple testing approach.
    Tosoian JJ; Sessine MS; Trock BJ; Ross AE; Xie C; Zheng Y; Samora NL; Siddiqui J; Niknafs Y; Chopra Z; Tomlins S; Kunju LP; Palapattu GS; Morgan TM; Wei JT; Salami SS; Chinnaiyan AM
    Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):563-567. PubMed ID: 36585434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
    Tosoian JJ; Zhang Y; Xiao L; Xie C; Samora NL; Niknafs YS; Chopra Z; Siddiqui J; Zheng H; Herron G; Vaishampayan N; Robinson HS; Arivoli K; Trock BJ; Ross AE; Morgan TM; Palapattu GS; Salami SS; Kunju LP; Tomlins SA; Sokoll LJ; Chan DW; Srivastava S; Feng Z; Sanda MG; Zheng Y; Wei JT; Chinnaiyan AM;
    JAMA Oncol; 2024 Jun; 10(6):726-736. PubMed ID: 38635241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.
    Haese A; Trooskens G; Steyaert S; Hessels D; Brawer M; Vlaeminck-Guillem V; Ruffion A; Tilki D; Schalken J; Groskopf J; Van Criekinge W
    J Urol; 2019 Aug; 202(2):256-263. PubMed ID: 31026217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
    Ankerst DP; Goros M; Tomlins SA; Patil D; Feng Z; Wei JT; Sanda MG; Gelfond J; Thompson IM; Leach RJ; Liss MA
    Eur Urol Focus; 2019 Jan; 5(1):54-61. PubMed ID: 29422418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    Sanda MG; Feng Z; Howard DH; Tomlins SA; Sokoll LJ; Chan DW; Regan MM; Groskopf J; Chipman J; Patil DH; Salami SS; Scherr DS; Kagan J; Srivastava S; Thompson IM; Siddiqui J; Fan J; Joon AY; Bantis LE; Rubin MA; Chinnayian AM; Wei JT; ; Bidair M; Kibel A; Lin DW; Lotan Y; Partin A; Taneja S
    JAMA Oncol; 2017 Aug; 3(8):1085-1093. PubMed ID: 28520829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
    Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
    Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
    Ochiai A; Okihara K; Kamoi K; Oikawa T; Shimazui T; Murayama S; Tomita K; Umekawa T; Uemura H; Miki T
    BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
    Buisset J; Norris JM; Puech P; Leroy X; Ramdane N; Drumez E; Villers A; Olivier J
    J Urol; 2021 Mar; 205(3):725-731. PubMed ID: 33080153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases.
    Crawford ED; Rove KO; Trabulsi EJ; Qian J; Drewnowska KP; Kaminetsky JC; Huisman TK; Bilowus ML; Freedman SJ; Glover WL; Bostwick DG
    J Urol; 2012 Nov; 188(5):1726-31. PubMed ID: 22998901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy.
    Feibus AH; Sartor O; Moparty K; Chagin K; Kattan MW; Ledet E; Levy J; Lee B; Thomas R; Silberstein JL
    J Urol; 2016 Oct; 196(4):1053-60. PubMed ID: 27140073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
    McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
    JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
    Ngo TC; Turnbull BB; Lavori PW; Presti JC
    J Urol; 2011 Feb; 185(2):483-7. PubMed ID: 21167519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.